Profluent is at the forefront of biological innovation, leveraging AI to design proteins that revolutionize medicine, agriculture, and beyond. Our platform specializes in creating new biology through AI-authored proteins, enabling breakthroughs in various fields. By combining machine learning and biology, we partner to solve complex challenges, offering AI-generated solutions for therapeutics, industrial enzymes, and more.
我们正在追踪 Profluent 的市场扩张
Profluent 的国际扩张与竞争对手的对比情况
Profluent你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Profluent你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
Profluent × Eli Lilly
已结束
Today we announced a landmark partnership with Eli Lilly and Company to use our AI models to design recombinases for genetic medicine—a collaboration valued at up to $2.25 billion before royalties.The goal: use Profluent's AI models to design recombinase editors capable of inserting long stretches of DNA at precise locations in the genome.Many genetic diseases involve hundreds of different mutations across patients–no single edit can address them all. Inserting a complete functional gene with a ...
已结束解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Profluent 的业务、市场和增长信号的快速解答。
